Liberty Wealth Management LLC Has $217,000 Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Liberty Wealth Management LLC lowered its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 27.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 8,978 shares of the company’s stock after selling 3,405 shares during the period. Liberty Wealth Management LLC’s holdings in Hims & Hers Health were worth $217,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the business. Quest Partners LLC increased its holdings in shares of Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after buying an additional 807 shares in the last quarter. Stonekeep Investments LLC boosted its stake in Hims & Hers Health by 5.5% in the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock valued at $410,000 after acquiring an additional 882 shares during the last quarter. Principal Securities Inc. boosted its stake in Hims & Hers Health by 48.2% in the fourth quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock valued at $74,000 after acquiring an additional 1,002 shares during the last quarter. Victory Capital Management Inc. boosted its stake in Hims & Hers Health by 1.9% in the fourth quarter. Victory Capital Management Inc. now owns 52,579 shares of the company’s stock valued at $1,271,000 after acquiring an additional 1,002 shares during the last quarter. Finally, Cadent Capital Advisors LLC boosted its stake in Hims & Hers Health by 1.5% in the fourth quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company’s stock valued at $1,745,000 after acquiring an additional 1,060 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 78,127 shares of Hims & Hers Health stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $29.62, for a total value of $2,314,121.74. Following the completion of the transaction, the chief executive officer now owns 109,956 shares of the company’s stock, valued at $3,256,896.72. This trade represents a 41.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Michael Chi sold 7,500 shares of Hims & Hers Health stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $26.00, for a total transaction of $195,000.00. Following the completion of the transaction, the insider now directly owns 193,601 shares of the company’s stock, valued at approximately $5,033,626. This trade represents a 3.73 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 969,191 shares of company stock worth $34,005,375. Insiders own 17.71% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. TD Cowen reiterated a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Bank of America reiterated an “underperform” rating and issued a $21.00 target price on shares of Hims & Hers Health in a report on Thursday, March 6th. BTIG Research assumed coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price on the stock. Citigroup reiterated a “sell” rating and issued a $27.00 target price on shares of Hims & Hers Health in a report on Thursday, March 6th. Finally, Leerink Partners increased their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a report on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $37.23.

Hims & Hers Health Trading Down 2.0 %

Shares of HIMS stock opened at $34.00 on Thursday. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98. The firm’s fifty day moving average price is $38.23 and its two-hundred day moving average price is $27.90. The firm has a market capitalization of $7.55 billion, a P/E ratio of 77.27 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.